Integrated analysis of long-term growth and bone development in pediatric and adolescent patients receiving bevacizumab-Reference-Cited by-同舟云学术

Integrated analysis of long-term growth and bone development in pediatric and adolescent patients receiving bevacizumab

Published:2018-10-30 Issue:2 Volume:66 Page:e27487
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Müller Hermann L.¹^ORCID,Merks Johannes H.M.²,Geoerger Birgit³,Grill Jacques³,Hargrave Darren⁴,Glade Bender Julia⁵,Gururangan Sridharan⁶,Navid Fariba⁷,Johnston Michael⁸,Bachir Jeanette⁹,Elze Markus C.¹⁰,Fürst-Recktenwald Sabine⁹

Affiliation:

1. Department of Pediatrics and Pediatric Hematology and Oncology; Klinikum Oldenburg AöR; Medical Campus University Oldenburg; Oldenburg Germany

2. Department of Pediatric Oncology; Emma Children's Hospital-Academic Medical Center (EKZ-AMC); Amsterdam The Netherlands

3. Department of Pediatric and Adolescent Oncology; Institut Gustave Roussy; Villejuif; France

4. Paediatric Oncology Unit; Great Ormond Street Hospital for Children NHS Foundation Trust; London United Kingdom

5. Division of Pediatric Hematology, Oncology, and Stem Cell Transplant; Columbia University Medical Centre; New York

6. Department of Neurosurgery; Preston A. Wells Jr. Center for Brain Tumor Therapy; McKnight Brain Institute; University of Florida; Florida

7. Department of Pediatrics; Children's Hospital Los Angeles; Keck School of Medicine; University of Southern California; California

8. Safety Science Lead; Genentech, Inc.; 1 DNA Way South San Francisco California 94080 USA

9. Pediatric Oncology; F. Hoffmann-La Roche Ltd.; Grenzacherstrasse 124 Basel 4070 Switzerland

10. Biostatistics; F. Hoffmann-La Roche Ltd.; Grenzacherstrasse 124 Basel 4070 Switzerland

Funder

F. Hoffmann-La Roche

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pbc.27487/fullpdf

Reference31 articles.

1. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme;Cohen;Oncologist,2009

2. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma;Friedman;J Clin Oncol,2009

3. Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with malignant solid tumors?;Tabone;Clin Cancer Res,2001

4. Increased serum VEGF in 13 children with Wilms’ tumour falls after surgery but rising levels predict poor prognosis;Blann;Cancer Lett,2001

5. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas;Eggert;Clin Cancer Res,2000

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. What is the Effect of Bevacizumab on Cartilage and Synovium in a Rabbit Model of Hemophilic Arthropathy?;Clinical Orthopaedics & Related Research;2023-04-10

2. Analysis and reporting of pediatric growth and development assessment from clinical trials: overview and challenges;Journal of Biopharmaceutical Statistics;2022-12-21

3. Single-agent Bevacizumab in the Treatment of Symptomatic Newly Diagnosed and Recurrent/Refractory Pediatric Cervicomedullary Brainstem Low-grade Gliomas: A Single Institutional Experience;Journal of Pediatric Hematology/Oncology;2022-04-13

4. Opportunities and Challenges in Drug Development for Pediatric Cancers;Cancer Discovery;2020-12-04

5. Spotlight on the treatment of infantile fibrosarcoma in the era of neurotrophic tropomyosin receptor kinase inhibitors: International consensus and remaining controversies;European Journal of Cancer;2020-09